Free Newsletter
Ranks of sales reps thinning
Fewer reps are knocking on doctors' doors these days. A consulting firm that advises most of Big Pharma says Pfizer, Sanofi-Aventis, and Bristol-Myers Squibb have all culled their herds of reps. And more companies will be following suit soon.
The cuts aren't a huge surprise; when most of the big drugmakers announced their restructuring-slash-layoff plans, they drew big targets on their sales operations. But other factors come into play, too, Jaideep Bajaj of ZS Associates told the WSJ Health Blog. Companies are backing away from their old, blanket-the-market sales models. Instead of sending five reps to chat up a doctor about the same med, they're sending only two or three.
- read the Health Blog item
- see a video interview with Bajaj
Related Articles:
Top 8 layoffs of 2007. Report
Pfizer to axe 2,200 sales jobs in realignment. Report
What to do with Avandia sales force? Report
Comments
Post new comment
Paid Research Reports
- The Specialty Pharma Market Outlook: Key players, new company growth models and emerging opportunities
- Investigating Clinical Trial Costs: Comparative analysis of trial cost components in key geographies
- Clinical Trial Recruitment Strategies: Optimizing patient recruitment and retention in late stage clinical trials
- Pipeline Insight: Therapeutic Cancer Vaccines - Prospect of first approval set to reinvigorate interest from major companies
- Stakeholder Opinions: Vaccines in Emerging Markets (Asia) - Opportunities in China, India, South Korea and Taiwan
- Big Pharma Performance Before, During and Beyond the Global Recession





